Videos

“As far as that point of max curve, I would say this is pretty definitive that this is something that needs to be done and changed within someone's practice,” says Landon Trost, MD.

Experts discuss grading, staging, and risk stratification of Non-Muscle Invasive Bladder Cancer (NMIBC). Panelists highlight differentiation between the risks of recurrence and progression, emphasizing the importance of categorizing patients into low, intermediate, and high-risk groups based on various factors, including tumor size, grade, and history of recurrence. The importance of continuous prospective observation of patients with NMIBC is emphasized.

"The study was done between April 2021 to 2023, so a 2-year span. It was surprising to find that 24% of our patients in that time span had opioid-free discharge," says Katherine Wang, MD.

Experts in urology discuss the importance of evaluation to accurately identify the stage and grade of NMIBC, which plays a crucial role in determining the risk category focusing on the distinction between low and high-grade tumors and the significance for each patient with NMIBC​​.

Christopher M. Pieczonka, MD and Jose De La Cerda, MD, MPH share their expertise in managing metastatic castration-resistant prostate cancer (mCRPC), focusing on the demographics in their distinct clinical practices and unique challenges they encounter nuances of treatment.  

In this Urology Times® episode, Dr. Kennelly, Dr. Kevin Benson, and Dr. Karyn Eilber discuss overactive bladder (OAB), focusing on its diagnosis, symptomatology, and patient populations most at risk, including gender and age-related factors.

Bogdana Schmidt, MD, MPH, outlines key bladder cancer research that was presented at this year’s Society of Urologic Oncology Annual Meeting.

“When it comes to this, I think having a great team around you is really so important,” says Bree Duncan, RN, BSN.

"Again, operating has more and more taken a backseat as the armamentarium of systemic medications, especially checkpoint inhibitors [and] combination treatments, has exploded," says Harras B. Zaid, MD.

“I love helping people to connect with their passions and to find and create the lives that they wish to create, both within the field of medicine and urology,” says Anne M. Suskind, MD, MS, FACS, FPMRS.

Janet Kukreja, MD, outlines key kidney cancer research that was presented at this year’s Society of Urologic Oncology Annual Meeting.

“I think if you were to ask what surprised me, I didn't expect it to have more of an effect on pain than anxiety,” says Heidi J. Rayala, MD, PhD.

“What it brought up is the point that where the field seems to be going is incorporating the PET imaging and the MRI imaging, and maybe PET MRI,” says Michael S. Cookson, MD, MMHC, FACS.

Specialists in the field of prostate cancer discuss their approaches for discussing rectal spacing with patients.

Comprehensive insights on the utilization of rectal spacers with proton beam radiation and brachytherapy in prostate cancer.

“It's exhausting and it's overwhelming, but traction has been gained and continues to be gained and we are making some meaningful, tangible differences,” says Mara R. Holton, MD.

Comprehensive insights on treatment considerations and managing immunotherapy-related adverse effects for patients with bladder cancer.

The panel discusses strategies for monitoring patients with non–muscle invasive bladder cancer and the potential role of biomarkers.

Expert perspectives on treatment options available for patients with bladder cancer and the role of trimodal therapy.

A panel of experts on bladder cancer provide an overview of the stratification, natural history, and treatment of bladder cancer.

An expert urologist reviews the clinical hallmarks of high-risk BCG-unresponsive NMIBC and discusses the unmet needs and treatment goals.

Neal Shore, MD, FACS, provides an overview of BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC), with a focus on patient presentation and risk stratification.

"Using the model of 100 implants per year, and assuming that we can reduce teaching visits by 1 during that 90-day global period, that translates into an estimated additional 3000 minutes of outpatient time that you have available to assist other patients," says Bradley Gill, MD.

“There has been a stage migration in part related to the availability of cross-sectional imaging, but there's still a proportion of patients who present with locally advanced disease,” says Harras B. Zaid, MD.

“I think being younger and going through something so scary, I think it's been really important to her to have someone with her throughout the whole process,” says Bree Duncan, RN, BSN.

"We're entering an era of more trauma-informed care, and trying to be sensitive to the fact that some of these invasive procedures can be a trigger for people because they're in that moment of feeling helpless and they don't have really a lot of control over the situation," says Heidi J. Rayala, MD.

"If you don't do a repeat curve assessment with each series of injections, you're possibly going to be missing the best location to do the injections," says Landon Trost, MD.

"The genomics assay was using biopsy tissue to help patients make decisions for the treatment choices. We also tested the effect of the assay on provider choice," says Adam B. Murphy, MD, MBA, MSCI.

"There are a lot of questions and issues regarding [topics] like body image and sexual function, and things like that, that also, being a woman in this role, I feel like they feel comfortable asking me those questions," says Bree Duncan, RN, BSN.

"Then [we] also started looking at somatic testing, because if you only stop at germline testing, you miss another 50% of patients who would have somatic alterations who have resistant prostate cancer," says Neal D. Shore, MD, FACS.